Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.57 |
| ▸ | TBK1 | Q9UHD2 | 12/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15673237 | 1.00 | KDR (0.57) | KDRTBK1CHEK1LCK | |
| SCHEMBL20055933 | 0.92 | KDR (0.47) | KDRTBK1LCK | |
| SCHEMBL8739147 | 0.91 | CHEK1 (0.52) | KDRTBK1CHEK1LCK | |
| SCHEMBL20461981 | 0.89 | USP30 (0.47) | KDRTBK1LCK | |
| SCHEMBL6125675 | 0.88 | KDR (0.52) | KDRTBK1CHEK1LCK | |
| SCHEMBL29470482 | 0.88 | KDR (0.52) | KDRTBK1CHEK1LCK | |
| SCHEMBL29470541 | 0.88 | KDR (0.49) | KDRTBK1CHEK1LCK | |
| SCHEMBL6125718 | 0.88 | KDR (0.49) | KDRTBK1CHEK1LCK | |
| SCHEMBL29470418 | 0.88 | KDR (0.59) | KDRTBK1LCK | |
| SCHEMBL6118520 | 0.88 | KDR (0.59) | KDRTBK1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773110-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | KDR 4125/4885TBK1 2106/4885CHEK1 395/4885 |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | KDR 4125/4885TBK1 2106/4885CHEK1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.